Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Buhl

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Infection|May 1, 1993
Prevalence of antibodies to hepatitis C virus among Omani patients with renal diseaseS H al-Dhahry, P N Aghanashinikar, M K al-Hasani, et al.
Transplantation Proceedings|October 1, 1992
Antibodies to hepatitis C virus in Omani patients with renal diseaseS H al-Dhahry, P N Aghanashinikar, M K al-Hasani, et al.
Ugeskrift for Laeger|March 18, 1996
[Survival time after the diagnosis of AIDS in the county of Funen]M K Hornstrup, A J Jørgensen, S L Andreasen, et al.
Scandinavian Journal of Immunology|March 18, 2000
Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patientsH Aladdin, C S Larsen, B K Møller, et al.
Scandinavian Journal of Immunology|March 17, 2001
Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patientsH Aladdin, C S Larsen, P Schjerling, et al.
Annals of Saudi Medicine|July 1, 1994
Hepatitis B, delta and human immunodeficiency virus infections among Omani patients with renal diseases: A seroprevalence studyS S Al-Dhahry, P N Aghanashinikar, H A Al-Marhuby, et al.
Transplantation Proceedings|October 1, 1992
Prevalence of hepatitis B, hepatitis delta, and human immunodeficiency virus infections in Omani patients with renal diseasesP N Aghanashinikar, S H al-Dhahry, H A al-Marhuby, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Infection|May 1, 1993
Prevalence of antibodies to hepatitis C virus among Omani patients with renal diseaseS H al-Dhahry, P N Aghanashinikar, M K al-Hasani, et al.
Transplantation Proceedings|October 1, 1992
Antibodies to hepatitis C virus in Omani patients with renal diseaseS H al-Dhahry, P N Aghanashinikar, M K al-Hasani, et al.
Ugeskrift for Laeger|March 18, 1996
[Survival time after the diagnosis of AIDS in the county of Funen]M K Hornstrup, A J Jørgensen, S L Andreasen, et al.
Scandinavian Journal of Immunology|March 18, 2000
Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patientsH Aladdin, C S Larsen, B K Møller, et al.
Scandinavian Journal of Immunology|March 17, 2001
Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patientsH Aladdin, C S Larsen, P Schjerling, et al.
Annals of Saudi Medicine|July 1, 1994
Hepatitis B, delta and human immunodeficiency virus infections among Omani patients with renal diseases: A seroprevalence studyS S Al-Dhahry, P N Aghanashinikar, H A Al-Marhuby, et al.
Transplantation Proceedings|October 1, 1992
Prevalence of hepatitis B, hepatitis delta, and human immunodeficiency virus infections in Omani patients with renal diseasesP N Aghanashinikar, S H al-Dhahry, H A al-Marhuby, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|November 25, 2011
Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infectionA Alsiö, A Jannesson, N Langeland, et al.
Journal of Viral Hepatitis|May 27, 2010
Hepatitis C treatment response kinetics and impact of baseline predictorsM Lindh, B Arnholm, A Eilard, et al.
Pageof 4